WHO EMRO | Multidrug-resistant disseminated tuberculosis in a 9-month-old infant

Multidrug-resistant tuberculosis (MDR) is an emerging problem in the world. It is a disease caused by strains of Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin, the 2 most powerful first-line anti-tuberculosis drugs (1–3). The World Health Organization (WHO) in 2013 reported that an estimated 12 million people worldwide had tuberculosis, with about 630 000 (5.3%) of these people having MDR tuberculosis (1).

[1]  D. Shingadia,et al.  Management of paediatric tuberculosis in leading UK centres: unveiling consensus and discrepancies. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  H. S. Schaaf,et al.  Managing multidrug-resistant tuberculosis in children: review of recent developments , 2014, Current opinion in infectious diseases.

[3]  Marcello Pagano,et al.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates , 2014, The Lancet.

[4]  M. Becerra,et al.  High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  H. Finlayson,et al.  Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Fielding,et al.  Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study , 2013, BMC Infectious Diseases.

[7]  J. Bayona,et al.  Tuberculosis in Children Exposed at Home to Multidrug-resistant Tuberculosis , 2013, The Pediatric infectious disease journal.

[8]  K. Floyd,et al.  Multidrug-resistant tuberculosis in children: evidence from global surveillance , 2012, European Respiratory Journal.

[9]  R. Gie,et al.  Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. , 2012, The Lancet. Infectious diseases.

[10]  N. Ford,et al.  Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[11]  P. Donald,et al.  Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Donald,et al.  Paediatric use of second-line anti-tuberculosis agents: a review. , 2012, Tuberculosis.

[13]  H. S. Schaaf,et al.  Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. , 2011, Paediatric respiratory reviews.

[14]  L. Saiman,et al.  Management of Pediatric Multidrug-Resistant Tuberculosis and Latent Tuberculosis Infections in New York City From 1995 to 2003 , 2008, The Pediatric infectious disease journal.